23-NHL-34-JJ-PMC (90009530): A Phase 1b Multicenter, Open-label, Study of JNJ-90009530, an Autologous Anti-CD20 CAR-T Cell Therapy in Adult Participants with Relapse

Grants and Contracts Details

StatusActive
Effective start/end date1/19/24 → 10/29/27

Funding

  • Janssen Research and Development LLC: $16,681.00